Drug intelligence / Profile preview

atezolizumab + erlotinib

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Atezolizumab + erlotinib is a combination therapy that pairs a PD-L1 inhibitor (atezolizumab) with an EGFR tyrosine kinase inhibitor (erlotinib). This combination was developed to enhance antitumor immunity and extend efficacy in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Atezolizumab works by blocking PD-L1, preventing its interaction with PD-1 and B7-1 receptors, thereby removing inhibition of immune responses. Erlotinib blocks the epidermal growth factor receptor (EGFR), inhibiting the tyrosine kinase enzyme and interrupting signaling pathways that drive cancer progression.

Targets

CD274 (Programmed cell death protein 1 ligand 1)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on atezolizumab + erlotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atezolizumab + erlotinib.

Explore the full profile